Overview
- The La Paz team engineered a tandem CAR-T that recognizes CD19 and CD22 to reduce antigen escape in B‑cell acute lymphoblastic leukemia.
- Patients received a tailored, low-intensity bone‑marrow transplant after CAR‑T to bolster persistence, avoiding total body irradiation.
- Since May 2020, 12 pediatric and young adult patients were treated under compassionate use, with four deaths and eight survivors, five disease‑free for more than two years.
- Findings were presented in Madrid and published in eBioMedicine, marking the first clinical report of this tandem approach in Spain and Europe by the unit.
- A formal clinical trial has begun at Hospital La Paz, with the first infusion in late July and additional infusions scheduled for November and December, funded by Fundación CRIS.